Baxter International Inc (BAX.N)
71.51USD
24 May 2013
$-0.64 (-0.89%)
$72.15
$72.05
$72.07
$71.33
703,413
808,260
$73.95
$48.98
About
Overall
| Beta: | 0.51 |
| Market Cap (Mil.): | $38,754.99 |
| Shares Outstanding (Mil.): | 541.95 |
| Dividend: | 0.49 |
| Yield (%): | 2.74 |
Financials
| BAX.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 17.23 | 34.04 | 34.30 |
| EPS (TTM): | 4.15 | -- | -- |
| ROI: | 15.69 | 19.04 | 18.43 |
| ROE: | 33.46 | 19.78 | 19.30 |
Baxter's Alzheimer's disease drug fails in late-stage trial
NEW YORK - In a blow for Alzheimer's patients, Baxter International Inc said it will scrap late-stage trials of its antibody treatment for the disease after the drug failed to improve cognitive decline and functional ability in patients.
UPDATE 2-Baxter's Alzheimer's disease drug fails in late-stage trial
* Baxter to stop late-stage studies of the drug for mild to moderate Alzheimer's
BRIEF-Baxter shares down after drug fails in late-stage trial
NEW YORK, May 7 - Baxter International Inc : * Shares down 2.6 percent in premarket trade after alzeheimer's drug fail
Baxter's Alzheimer's disease drug fails in late-stage trial
May 7 - Baxter International Inc said a late-stage study of its experimental drug to treat Alzheimer's disease failed to reduce the decline of cognitive functions and preserve functional abilities.
Baxter posts lower earnings on acquisition-related expenses
- Baxter International Inc on Thursday said quarterly net earnings fell slightly, as expected, on acquisition-related costs.
UPDATE 2-Baxter posts lower earnings on acquisition-related expenses
* Strength in Bioscience division offset weakness in medical products unit
Baxter posts lower earnings on acquisition-related expenses
- Baxter International Inc on Thursday said its quarterly net earnings fell slightly, as expected, on acquisition-related costs.
Baxter posts lower earnings on acqusition-related expenses
April 18 - Baxter International Inc on Thursday said its quarterly net earnings fell slightly, even as sales rose, as acquisition-related costs ate into profits.
Manatee death toll rises in Florida even as toxic algae ebbs
TAMPA, Florida - A deadly algae bloom that killed a record number of manatees has dissipated, though the death toll for the endangered sea mammals continues to rise, Florida wildlife officials said on Thursday.
Baxter profit higher; sales seen rising 10 percent in 2013
- Medical device and bioscience company Baxter International Inc reported higher quarterly earnings on Thursday and forecast sales growth of 10 percent for 2013.
Competitors
| Price | Change | |
|---|---|---|
| Boston Scientific Corporation (BSX.N) | $9.08 | -0.08 |
| Johnson & Johnson (JNJ.N) | $86.82 | -0.39 |
| Abbott Laboratories (ABT.N) | $37.76 | +0.28 |
| Roche Holding Ltd. (ROG.VX) | CHF253.10 | +2.40 |
| Pfizer Inc. (PFE.N) | $29.04 | -0.07 |
| Wyeth Limited (WLED.NS) | Rs780.45 | -1.45 |
| Hospira, Inc. (HSP.N) | $35.08 | -0.10 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (BAX). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Jefferson Research
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

